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1. Introduction 
In Mexico, Influenza virus infections occur more frequently during the winter with small 
peaks throughout the year. In April 2009, an epidemic arose from the emergence of a new 
Influenza A virus, whose devastating effect reflected significantly in Mexico city. Numerous 
patients with Influenza-like severe symptoms were attended at the Instituto Nacional de 
Enfermedades Respiratorias Ismael Cosio Villegas, Mexico (INER) and in many cases 
required hospitalization. The INER, in collaboration with the Dirección General de 
Epidemiología (Mexico) and the Instituto Nacional de Referencia Epidemiológica, Mexico 
(INDRE) marked the first guidelines for the management, diagnosis and treatment of 
Influenza-illness in Mexico. The INER is considered one of the leading centers for the care of 
critically respiratory-ill patients, and was one of the first institutions to describe the clinical 
presentation and death in the initial period of outbreak (Acuña, 2010; Manjarrez et al., 2003). 
The pandemic that occurred in 2009 in Mexico, took a different tack in contrast to other 
countries with respect to the frequency, severity and number hospitalized patients with 
mortality and greater affection in healthy young people. Influenza is a respiratory illness 
caused by viruses of the same name. Each year, seasonal flu viruses originate occasional 
epidemics. The name "influenza" comes from the belief that disease was caused by a 
negative supernatural influence, that is, a malign influence, or that the stars have influence 
on the occurrence of the disease (Acuña, 2010; Manjarrez & Arenas 1999). 
In Mexico, there exist accurate records of 13 severe epidemics occurred during: 1667, 1734, 
1805, 1806, 1826, 1837, 1846, 1891, 1899, 1918, 1920, 1957 and 1969, being reported the highest 
rates of mortality in the year of 1919 (Acuña, 2010). Infections are most common during the 
winter and small outbreaks over the year (Manjarrez et al., 2003, 2010). 
2. Characteristics of the influenza virus 
2.1 Classification and nomenclature 
Influenza viruses are grouped in the Orthomyxoviridae family including three types: A, B 
and C. The A gender is the most common, infecting birds and mammals, including humans; 
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it can causes epidemics and pandemics with high rates of morbidity and mortality. 
Influenza viruses B and C are less frequent, mainly infecting humans and causing moderate 
epidemics or outbreaks (Manjarrez & Arenas 1999; Manjarrez et al., 2010; Souza, 2011; 
Zambon, 1999). According to the antigenic characteristics of hemagglutinin (HA) and 
neuraminidase (NA) proteins, influenza viruses are subdivided into subtypes. To date, it 
has been characterized sixteen HA subtypes and nine NA antigenic subtypes, all of which 
are found in aquatic wild birds. The international nomenclature used to describe the 
different influenza virus is to appoint the following characteristics: a) gender of the virus A, 
B or C; b) host type is ignored when it comes from human c) place of isolation; d) case 
number in the laboratory; e) year of isolation; f) HA and NA subtype of the virus which is 
written in parentheses. An example of a human virus isolated in Mexico in 2009 was 
described as "A / Mexico / INDRE / 4487 / 2009 (H1N1)" (Dawood et al., 2009; López-
Cervantes et al., 2009; WHO, 2009a). 
2.2 Structure 
Viruses range in size from 80 to 120 nm in diameter having a pleomorphic or spherical form. 
They have a segmented genome (7 and 8 fragments) of single stranded RNA of negative 
polarity, encoding 11 proteins being two glycoproteins. Fragments 1, 2 and 3 encode 
proteins PB1, PB2 and PA those are part of the polymerase complex and are involved in the 
synthesis of RNA. Segment 4 encodes the HA protein which is the receptor that binds to the 
cell. It is synthesized as a monomer which undergoes posttranslational modifications and is 
activated by a host protease that cuts it into two fragments, HA1 and HA2, exposing the 
peptide fusion in the aminoterminal region of the HA2 fragment, allowing fusion of the 
viral envelope with the endosome in order to release the genome into the cytoplasm. The 
mature protein is a trimer formed by a stem that is inserted into the membrane and three 
globular regions. The globular region has an amino terminal region, where are localized the 
antigenic sites that are surrounding the receptor binding site (Manjarrez & Arenas, 1999; 
Zambon, 1999). The fragment 5 encodes the nucleoprotein (NP), forms a complex with RNA, 
protects the genome and is involved in replication. Segment 6 encodes for the 
neuraminidase (NA), the mature protein consists of a stalk and a globular head constituted 
of 4 subunits each with a catalytic site. Its role is to remove sialic acid residues of the 
membrane of the infected cell, allowing the newly synthesized virions were not clumping 
together and released properly. Segment 7 corresponds to the M1 and M2 proteins that are 
synthesized by a overlaid reading frame. M1 protein surrounds the nucleocapsid and M2 is 
located in the membrane and functions as an ion channel allowing the transport of protons 
to the endosome and is the target for antiviral drugs (e.g. amantadine). Segment 8 encodes 
for two nonstructural proteins: NS1 and NS2, that is, not belonging to the virion; these 
proteins are synthesized when the cell is infected. The NS1 protein inhibits the production 
of interferon; however, the function of NS2 protein is still unknown. Recently, it has been 
described the PB-1-F2 protein with a pro-apoptotic function (Manjarrez et al., 2010; Zambon 
2001; WHO, 2002). Influenza viruses have a high rate of molecular variation, changes that 
can cause epidemics and pandemics. These changes are given by different factors: the nature 
of the virus (RNA replication needs of a RNA polymerase, which is inefficient to correct 
errors, so that mutations are common, in addition, the genome is segmented allowing 
increased recombination. Influenza A viruses infect humans as well as a variety of animals, 
this allows high levels of recombination between viruses from two or more hosts. Among 
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the known mechanisms of variation there is the “antigenic drift”, which are small changes 
that lead to mutations, mainly in the two viral glycoproteins (HA and NA). This variation 
allows an ineffective function of the host neutralizing antibodies, contributing to the need of 
renew vaccines annually. Other variation mechanism that is less frequent is the “antigenic 
shift”. This mechanism allows the generation of new subtypes that can arise by 
recombination and rearrangement of entire segments of genes (Figure 1). 
 
Fig. 1. Pandemic Influenza Virus. The new virus has a reassortant, the changes are shown in 
different colors: PB2, Classical North American Swine H1N1/Triple reassortant swine 
H3N2/A avian-like; PB1, Classical North American Swine H1N1/Triple reassortant swine 
H3N2/A avian-like; PA, Triple reassortant swine H3N2/A avian like; HA, Classical North 
American Swine H1N1; NP, Classical North American Swine H1N1/Triple reassortant 
swine H3N2; NA, Eurasian Swine N1; M Eurasian Swine; NS, Classical North American 
Swine H1N1/Triple reassortant swine H3N2.  
2.3 Viral transmission and pathogenesis 
The virus enters through the nasopharyngeal region for aerosols and droplets expelled to 
talking, coughing and sneezing, with hands and objects contaminated with aerosols and can 
last for hours or days on contaminated surfaces. The virus infects mucus-secreting epithelial 
cells and ciliates cells. 
The HA binds to cell receptor, after incubation for one to three days, the virus replicates 
rapidly and infects neighboring cells. The virus causes cell damage, which alters the cilia 
activity, with increased secretion of mucus. To get out and infect other cells the NA reduces 
the viscosity of the mucus. 
Desquamation on the epithelium causes respiratory symptoms and signs, involving the 
respiratory tract’s natural response and promotes bacterial incorporation. Other damage is 
on the submucosal edema, which in turn may lead to hyaline membrane disease, 
emphysema and alveolar necrosis. The inflammatory process may break bronchi, 
bronchioles and alveolar regions. All these events originate characteristic initial symptoms 
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of infection such as: fever, chills, and widespread pain, particularly muscle aches, headache, 
anorexia and prostration. The local monocytes and lymphocytes are the primary response 
and interferon is effective against the virus. The virus induces an effective humoral 
response, it is important in recovery, but should be considered that the antibody response is 
specific for each variant of the virus, while the T lymphocytes and macrophages is general 
and depending on the damage and the condition of host, epithelial repair can take up to a 
month. Start the virus infects upper respiratory tract but, it can reach low way causing 
bronchitis, bronchiolitis and pneumonia. 
3. A new pandemic caused by a new influenza A virus in 2009 
Usually in Mexico, Influenza infections occur in winter (Cabello et al., 2006; Vandale et al., 
1997); however, in March 2009, began to be evident the first signs of influenza infections, an 
unusual time for the viral infection. The spread was fast and it was extended to many 
countries. On April 30th, the World Health Organization called officially an "H1N1/09 
Pandemic Virus" (Dawood et al., 2009; Garten et al., 2009; López-Cervantes et al., 2009; 
Updated 2009; Vaillant et al., 2009; WHO, 2009). So, on June 11th, the WHO declared a 
pandemic. Mexico City showed the most serious cases with numerous deaths, the causal 
agent was found to be a new type of influenza virus. To June 15th, in 76 countries the virus 
was detected with 35,928 cases of infection and 163 deaths. By July 17th the virus had spread 
to 135 countries, with 101,250 confirmed cases. In Mexico, July 17th, Mexican Ministry of 
Health reported that the virus was present in all 32 states of the country; the number of 
cases was 13,646 with 125 deaths. Of the 70.4% recorded deaths was found in the age group 
of 20 to 54 years, the deaths accounted for 0.9% of total deaths, of which 52% were women, 
most of whom were housewives (Secretaria de Salud de Mexico, 2010b) 
When the pandemic virus appears, there may be several periods of outbreaks with a range 
of 3 to 9 months between them. The pandemic in Mexico occurred in three outbreaks. The 
first began with the epidemiological alert on April 17th, and lasted for about a month. The 
second was in the months of June-July in the Southeast, although the magnitude was much 
smaller than the first outbreak. The third began in September 2009, mainly in northern and 
central Mexico. 
On November 27th, the WHO informed that more than 207 countries had reported the 
presence of the new virus (Vaillant et al., 2009; WHO 2009). Here is a brief narrative of the 
activities, measures and experiences that took place in the INER at the onset of the influenza 
pandemia. 
4. Approach of influenza medical cases at the respiratory emergency unit  
It was received a disproportionate demand of patients showing severe acute respiratory 
infection (SARI) in addition to other possible influenza patients with other pathologies. 
Therefore, the mechanisms of classification, prioritization and selection of hospital 
management were reinforced. For the epidemic emerged in Mexico were implemented three 
phases of Triage: 
1. Initial Triage. Patients with potentially SARI were separated from those with other 
diseases. Patients were required to fill an application form assessed by a physician.  
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2. Second Triage. Patients with respiratory symptoms related to influenza A H1N1 
infection or potential epidemic/pandemic infection were removed from patients with 
infection by other viruses or bacteria.  
3. Third Triage. It was defined the location of patient: home, hospital ward or intensive 
care. 
Triage is useful for infection control and epidemiological monitoring, as well as the 
rationalization and organization of the Respiratory Emergency Unit overcoming potential 
responsiveness. 
Classification systems include schemes to determine the severity of community-acquired 
pneumonia and influenza; this classification is not necessary when the risk groups are 
different so they could be misclassified probably conducing to an increased mortality in young 
patients during the pandemic. The proposed schemes should only be considered as a guide 
and do not replace the clinical criteria (Corrales, 2010; WHO, 2007). Among the schemes 
implemented are: Criteria for classification of patients; calculation Score: Pneumonia Severity 
Index for Adult (PSI/PORT ), which consider the characteristics of patient demographic 
factors, comorbidity disease, findings on physical examination, laboratory and/or 
radiographic findings (ranked by points) (Corrales 2010, Osterholm 2006); Risk Rating PORT 
severity index of pneumonia, and Scoring System CURB-65 (See next box).  
 
SCORING SYSTEM CYRB-65 
FEATURES POINTS 
Confusion +1 
Urea> 7mmol/L (20 mg/dL) +1 
Respiratory rate > 30 breaths per min. +1 
Blood pressure (systolic > 90  
or diastolic < 60 mm Hg) 
+1 
Age > 65 +1 
  
Patient Score Site Recommended care 
0-1 outpatient 
2 Ward 
3-5 
Hospital room or 
intensitive care unit 
  
  
Table 1. Criteria for classification of patients 
Unfortunately, all efforts to use these scales in viral pneumonia, especially those caused by 
human influenza virus A H1N1 during the 2009 pandemic have been unsuccessful and 
unreliable. 
5. Considerations for selection of patients on critical care medicine 
It was considered two components of Triage: 1) prioritize patients and 2) management 
and resource optimization. This system is not error-free (overtriage or undertriage). 
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Experts in disaster situations have established a classification system or Triage at the 
Emergency Department or Intensive Care Unit. This system consists in to establish a color 
system for assessment and patient selection: green (patient will survive or not receiving 
support), yellow (patient will survive in case of delayed medical care); red (patient needs 
immediate intervention to survive), blue or black (patient will die despite the best efforts 
of Physicians).  
However, the situation that we live during the first outbreak of pandemic influenza 
experienced at the INER during March to May was truly different and represented a 
challenge for the treatment of many patients with severe respiratory failure requiring 
mechanical ventilation or in shock. 
Unable to attend all patients because the Department of Critical Medicine has only 9 
intensive care beds (2 of them for pediatric patients) and 5 intermediate care beds, it was 
decided to transform the cubicles of pediatric patients into care beds for adults. This action 
allowed us to had 15 beds. 
Moreover, the conversion took place in hospital besides enabling a pavilion, also allowing 
the use of this area for the care of patients with influenza A H1N1 pneumonia with or 
without need for mechanical ventilation in this situation; we had to suspend the no 
outpatient urgent and elective surgery activities in order to concentrate human resources in 
these areas. According to these conditions, patients most likely to survive (e.g. under 65 
years old without comorbidity in end-stage cancer, without multiple organ failure and/or 
without terminal renal failure with requirement of replacement therapy because there was 
no equipment for (renal replacement T-Hemofiltration and hemodyalisis). They were 
accepted preferably in the Department of Critical Medicine, that was our initial triage 
system. We organized a committee Influenza Hospital (Bautista, 2010; Funk et al., 2010). 
Patients who were not chosen for their attention to a critical care area, represented a difficult 
situation because although they should be given immediate attention, establish a prognosis 
according to their severity and set neatly in the family may even be conflicting even among 
physicians in different areas within the hospital, but in a pandemic is only a problem in 
addition to a long list that puts the resource limit with which it has in every way, physical 
area, technology, inputs and humans. To decide which patients should be hospitalized and 
then locate them in the level of care they should receive may be more complex (outpatient 
observation in the emergency room, hospitalization, need for critical care or in spite of the 
latter by requiring extremely serious and not being able to triage proportions) creates a 
serious problem. 
Regarding to resources, it was necessary to make a list indicating the available material and 
which must have, number of mechanical ventilators, beds, protective equipment for 
personnel, drugs and so on. It should be performed together involving CEOs, medical and 
administrative personnel, nursing, Medical Committee etc., for monitoring and 
troubleshooting. Several aspects of the strategy included area marking, media provide 
reports to the press and interested staff, health staff compare with that account and assign 
roles and responsibilities, flexibility of spaces, since in an emergency usually mechanical 
ventilators, beds in the different units and services which are not enough to make 
adaptations (Sandoval, 2010). 
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This indicates that the triage is necessary for the success of a medical contingency. Triage 
has medical basis for their development. It is necessary that each hospital unit set their 
standards according to their structure and needs (Sandoval, 2010; Rubinson et al., 2008). 
6. Characteristics of the clinical cases  
Clinical cases of influenza-like illness showed respiratory insufficiency and later was 
confirmed the infection with influenza A (H1N1) virus. Patients were mostly young 
individuals, in less than one year had the highest rates, with a gradual decrease in inverse 
proportion to the age (Figure 2). However, it was found that complications occurred in 10% 
of adults who were hospitalized. With increase age after 35 years, it was shown the highest 
percentage (20%); people over 65 years-old required hospitalization. Same behavior was 
observed with regard to lethality, with an increase on 20 to 35 years-old group as well as in 
the age group over 65 years-old. Because of the severity of respiratory damage, a large 
number of patients required intubation (mean age: 37 years-old). Fifty percent of all cases 
were female with no significant differences in mortality and hospitalization. Co-morbidities 
were frequent and varied in patients: the most common were diabetes mellitus, 
hypertension, chronic obstructive pulmonary disease, obesity, smoking and pregnancy 
(Bojorquez et al., 2010; Behazin et al., 2009; Cabello et al, 2012 in press). Patients who 
presented with a severe respiratory illness were immediately isolated.  
 
Fig. 2. Influenza cases in Mexico by age group from 11th March to 27th May, 2009. Data 
obtained from: Fajardo, et al. 2009. 
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7. Clinical manifestations 
In general, the clinical manifestations observed during the infection tend to be similar with 
any subtype of influenza virus. The characteristics of the disease included signs and 
symptoms ranging from mild to severe manifestations. In Mexico, at the beginning of the 
pandemic of 2009, it was introduced a delay in diagnosis because the patients first consulted 
a general practitioner who were given treatment with antibiotics. Once identified the 
circulation of a new influenza virus, most patients (over 50%) had self-limiting illness 
without medical care. Complicated cases arrived at a hospital were treated with antiviral 
treatment, considering that if 72 hours after was not an improvement; illness were managed 
in accordance with the recommendations for progressive disease treatment. In mild cases, 
damage was mainly in upper respiratory tract, and the main symptom was dry cough. 
When the infection spreads to the lower airways, bronchus and lung parenchyma, it causes 
pneumonia with cyanosis and sometimes bloody sputum. Signs and symptoms were as 
follows: 
Cough. Cough occurred between 90 and 100% of cases. Initially, illness was unproductive 
and then, in 33% of patients showed bloody sputum.  
Dyspnea. It was presented in 65-73% of patients with complicated disease, so it was 
considered as the main symptom indicating the severity of the disease evolution. This 
symptom was presented in 86% of patients with pneumonia and in 90% of patients 
requiring management in the Intensive Care Unit (Cabello et al, 2012 in press; Pérez-Padilla 
et al., 2009; Echeverría-Zuno et al., 2009; Domínguez-Cherit et al., 2009). Sore throat and 
runny nose was observed in patients with upper respiratory tract infection (75% of patients) 
and in patients requiring hospitalization (35%) (Pérez-Padilla et al., 2009). 
Sore throat and rhinorrhea. It was noted that patients with upper respiratory tract infection 
occurred in 75 and in patients requiring hospitalization, about 35% had (Pérez-Padilla, 
2009). 
Fever. Temperatures over 38°C were considered as the main systemic symptom increasing 
with the severity; in mild cases occurred in 40-50% while in severe cases occurred up to 
100% (Cabello et al, 2012 in press; Pérez-Padilla et al., 2009; Echeverría-Zuno et al., 2009).  
Headache. It was more common at the onset of the disease and was more frequent in 
outpatients than inpatients. We recorded 22 to 88% of the cases (Cabello et al, 2012 in press; 
Pérez-Padilla et al., 2009; Echeverría-Zuno et al., 2009; Domínguez-Cherit et al., 2009).  
Myalgia and arthralgia. It was reported mainly in muscles of the lower extremities and 
occurred between 40 to 70% of total of the cases. 
Gastrointestinal symptoms. Usually, seasonal influenza has a frequency of 5% while 
influenza caused by the new virus was reported between 10 to 30% of cases and was more 
common in children. It has been suggested, although not proven a fecal-oral transmission 
(Petrosillo et al., 2009; Ramírez et al., 2010).  
Diarrhea, nausea and vomit. In seasonal influenza are rare, but when the disease is more 
severe it has been reported in 3 to 5% of the patients. At the INER the new virus was 
reported in 10% of severe cases in comparison with other medical centers in which it was 
reported a positive infection in 20 to 38% of cases. 
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At the beginning of the outbreak, there was a transmissibility rate of 1.2% and a mortality 
rate of 0.4%. Subsequently it was reported new ranges of mortality, from 0.20 to 1.23%, of 
which the lower ranks were in Europe and the highest in Mexico. It has been reported in 
Mexico during the pandemic that in Mexico city was the highest number of deaths in 
comparison with other countries, and the increased risk of death from pneumonia included 
people over 60 years of age. At the INER from April 17th to December 4th, 2009, it was 
reported a total of 763 cases of pneumonia with 138 deaths accrued. There have been some 
possible explanations for this situation: being the first country in which began the outbreak, 
the virus had an increased pathogenic activity and spread, therefore, patients to be unaware 
that this was a new virus, failed to get adequate medical care. In addition, medical staff was 
not aware of the existence of new viruses conducing to mismanagement of patients. In 
children, the clinical picture of the new virus influenza A (H1N1) infection was launched as 
seasonal flu-like infection, fever greater than 37.5°C, cough, chills, headache, nausea, 
hyperoxia, lethargy, muscle pain and fatigue, but added gastrointestinal symptoms such as 
diarrhea and vomiting. The clinical spectrum of symptoms was mild to progressive 
respiratory distress syndrome, requiring mechanical ventilation, associated with organ 
failure and death. Finally, the main causes of death were respiratory failure, sepsis, 
dehydration and electrolyte imbalance (Cabello et al, 2012 in press; Cano et al., 2010; Fajardo 
et al., 2009; Garrido et al., 2010). 
8. Histopathological features of the disease detected in patients admitted to 
the INER 
8.1 Tracheobronchial abnormalities 
The seasonal influenza virus A and B have an affinity for epithelial cells and produce 
ciliated epithelial erosion and ulceration and inflammatory infiltrate in the subepithelial 
layer, initially neutrophils and later by lymphocytes. Macroscopic autopsy confirmed 
patients infected with influenza A (H1N1) virus showing extensive hemorrhagic 
tracheobronchitis, ciliated columnar epithelium with extensive necrosis, intraluminal 
desquamation of epithelial cells with partially eroded basement membrane, few epithelial 
cells with cytoplasmic vacuolization and deposition of hyaline membranes focally. In 
patients who died within hours after hospital admission showed no inflammatory cells. 
Patients with longer history had few neutrophils in the lamina propia of the mucosa while in 
patients with longer time of hospitalization, it was observed numerous lymphocytes 
infiltrating the tracheobronchial wall. Other findings observed were: vascular congestion 
and interstitial edema. In past pandemics caused by influenza virus infection, these 
observations have been described by other authors (Taubenberger & Moreno, 2008; 
Jeannette et al., 2006). 
8.2 Pulmonary histopathological findings  
While the new virus caused several deaths, macroscopic lung findings were not very 
different from those described in seasonal influenza. The post mortem biopsy specimens and 
autopsy cases showed massive pleural effusion predominantly on the right, lung weight 
and larger size, shiny outer surface, heterogeneous areas of congestion and hemorrhage of 
bright pink and red violet color; these lungs were poorly demarcated, confluent, giving a  
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Fig. 3. Micrographs of damage in the lung parenchyma and tracheal: A) Respiratory 
bronchiole epithelial ulceration, fibrin plugs and scaling of columnar cells and macrophages; 
B) Alveolar edema and hemorrhage; C) Necrosis of the alveoli with deposits of hyaline 
membranes and alveolar edema with heavy infiltration by neutrophils and congestion of the 
capillaries; D) Interstitial edema with infiltration by neutrophils, capillary dilation and 
intraalveolar edema; E) Wall of the trachea is observed denudation of the respiratory 
mucosa; F) Hyperplasia of type II pneumocytes and cytomegaly; G) Areas of bronchiolitis 
obliterans due to proliferation of fibroblasts; H) necrotizing vasculitis surrounded by acute 
inflammatory infiltrate. Hematoxilyn and eosin stain (HE). 
marbling pink to red-violet color, soft consistency and some consolidated areas; some cases 
showed lobar consolidation (Vázquez et al., 2010). Microscopically, most cases showed 
diffuse alveolar damage in exudative phase, with marked alveolar epithelial necrosis and 
hyaline membrane formation up to 5 microns thick, with focal dilatation of alveolar spaces, 
intra-alveolar hemorrhage, edema, hyperplasia and scaling of Type II pneumocytes and 
macrophages in the alveolar pinocytosis. In some macrophages and pneumocytes cytopathic 
damage was observed characterized by nucleomegaly, thrombosis with appearance of 
frosted glass capillary and necrosis of alveolar septa. It was identified areas of congestion 
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and capillary alveolar wall thickening. According to the evolution time and complications, 
leukocyte infiltration between predominantly neutrophilic and lymphocytic lineage was 
little more intense in areas with few megakaryocytic intracapillary necrosis. Thrombosis of 
the capillary rise of the alveolar wall necrosis in large areas, confluent with fibrin exudate 
and loss of alveolar epithelium adjacent to the intra-alveolar hemorrhage and diffuse 
alveolar damage of acute lung inflammation was observed as well as occasionally 
peribronchial and bronchiolitis with necrosis and ulceration of the epithelium, which 
corresponds to the typical histological pattern of viral-induced lung damage. There were 
signs of tissue repair, regeneration of the bronchiolar and alveolar epithelial hyperplasia, 
and squamous metaplasia of pneumocytes (Vázquez et al., 2010). In the interstitium and 
bronchioles (bronchiolitis obliterans) was observed proliferation and reorganization of 
fibroblasts (Masson bodies) as well as large areas of fibrosis. Other authors (Guarner et al., 
2000) detected influenza virus infection in bronchial epithelium and submucosal glands of 
the trachea, bronchi and bronchioles. Figure three shows some of the histopathological 
findings. 
8.3 Findings using electron microscopy 
By examining several sections of the lung, the ultrastructural changes that were detected 
were: alveolar capillaries with numerous erythrocytes and some leukocytes, airspaces with 
Type II pneumocytes, with projections in discrete cytoplasmic membrane and occasionally 
adjacent debris. In the cytoplasm of some macrophages phagocytosed erythrocytes and 
autophagosomes (electron concentric deposits) were observed. Type II pneumocytes have 
abundant cytoplasm with mitochondria-like swollen smooth endoplasmic reticulum which 
tend to lose their crests; in addition, round nuclei with little heterochromatin attached to the 
inner nuclear envelope and a prominent nucleolus were found. Low viral particle number, 
ranging from 93 to 150 nm in diameter, was visualized in the cytoplasm of some alveolar 
epithelial cells. At different stages of the viral cycle, it was observed vacuoles and 
endosomes emerging from the cytoplasmic membrane of the pneumocyte. Alveolar 
epithelial cells showed moderately dilated smooth endoplasmic reticulum, presence of 
electron-slightly larger vacuoles (compatible with pulmonary surfactant), round to oval 
nuclei with little heterochromatin in the nucleoplasm and prominent/eccentric nucleoli 
(Vázquez et al., 2010). 
9. Imaging studies 
The first choice study was simple plate-ray or chest X-ray; the techniques used were the 
portable X-ray and teleradiographs. The most frequent pattern was mixed alveolar and 
interstitial, predominantly axial and bilateral basal respecting the periphery. Cases with 
rapid progression were observed following the consolidation respecting upper lobes 
without associated lymphadenopathy or pleural effusion. In severe cases, the progression 
was rapid and affection pattern reverted to 18 to 30 days. Some patients underwent high-
resolution computed tomography. Reconstructions were completed after 1 second, 
reconstruction algorithm and the high end of a forced inspiration, also took a series on 
forced expiration from lung apex to the diaphragmatic dome. The pattern found was mixed 
(interstitial and alveolar), predominantly interstitial type, characterized by areas of 
unpolished glass with a trend of consolidation, predominantly basal bilateral, axial 
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compliance lung apices sometimes patchy pattern. Associated effusion or lymphadenopathy 
were not found. Expiratory phase showed areas of air trapping (Abella, 2009; Alva & 
Perdigón 2010; Chowell et al., 2009). 
Figure four shows some of the findings in radiographic images. 
 
Fig. 4. Male patient 47 years of age diagnosed with H1N1 and 15 days earlier. A) The 
radiograph shows bilateral alveolar opacities; B ) TAC Atypical pneumonia, and diffuse 
alveolar damage. 
10. Respiratory therapy strategies for the management of patients with 
influenza A H1N1 virus 
One of the important points in the respiratory therapy strategy involves knowing all the 
devices used in patients with some degree of respiratory failure and that includes 
everything from ways to deliver oxygen, nasal cannula, masks in all its varieties combining 
with moisture systems and the need to administer bronchodilators and/or inflammatory 
airway. In patients infected with the influenza A H1N1 virus, the use of bronchodilators and 
inhaled anti-inflammatory drugs is required. It is recommended the use of thermal units 
with systems of automatic filling and thermal self-regulation, reducing the handling of 
samples and the risk of dispersion of viral particles into the environment. Is important to 
avoid the use of thermal units that promote water condensation in the ventilator circuit. This 
situation requires the frequent disconnection of the circuit promoting environmental 
contamination with viral particles. Filters/nose or HME filter (Humidity Moisture 
Exchange) generate passive moisture and prevent the passage of bacteria into the patient 
allowing the safely change of filters every 7 days (Garcia & Garcia, 2010; Thorpe & Darcy 
2009). We recommend active humidity systems for mechanically ventilated patients with 
high PEEP and are candidates for the use of bronchodilators. If the patient does not require 
the use of bronchodilators or other medications in nebulizer, nose/filter is a good choice. In 
the case of circuits of mechanical ventilation, the new generation ventilators compensate for 
leaks in the circuit. These systems can be cleaned safely each 7 days, even 15 days, in both 
cases, as long as the circuit does not show contaminating secretions. The interaction between 
the circuit and thermal units, and misting systems or aerosol delivery are important and we 
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recommend a combination in the setting to the minimum necessary to disconnect or unplug 
it. Disconnection is suggested for each clamp on the tracheal cannula after the inspiratory 
phase, decreasing the risk of viral contamination into the environment. The processes of 
oxygenation in patients with influenza include devices such as nasal prongs, masks (opened 
and closed; high and low flow). All these systems have shown that in the process of 
exhaling, sneezing and coughing are generated particles including viral particles. The 
oxygen delivery systems in patients with influenza and respiratory failure depend on the 
severity of respiratory symptoms, the greater hypoxemia, and more oxygen is required. The 
administration by nasal cannula provides an inspired oxygen fraction up to 40% in order to 
maintain or improve oxygen saturation (oxygen partial pressure above 60 mmHg) (Garcia & 
Garcia, 2010; Tellier, 2009; Jefferson et al., 2009). 
It still necessary studies to optimize the management of patients with influenza and to 
generate techniques to minimize risks to medical staff, nurses, technicians and anyone who 
interacts with the patient. 
11. Extrapulmonary complications in pneumonia due to influenza A H1N1 
Pneumonia caused by Influenza Virus A (H1N1) corresponds to Acute Respiratory 
Distress Syndrome (ARDS) with increased intra-alveolar hemorrhage. In ARDS, the 
increased mortality due to no respiratory complications is common in the critically ill 
patient; 16% of patients may develop a complication that includes: sepsis and septic 
shock, myocarditis and pericarditis, acute encephalitis, rabdomielitis, acute renal failure, 
liver failure and/or disseminated intravascular coagulation. In patients with chronic 
obstructive pulmonary disease or asthma, viral infections are frequent causes of 
complications. 
12. Respiratory failure and multi-organ in Influenza-induced illness 
In the first cases of influenza in Mexico, that included 18 patients, people required 
hospitalization, oxygen therapy and required mechanical ventilation due to ARDS. Among 
the reported data it can be included: elevated body mass index elevated LDH or CPK as well 
as history of smoking. Epidemiological data of patients with respiratory failure, who 
required intensive care, have been described in two series of patients in Mexico City and 
Canada (Echeverría-Zumo, 2010; Kumar et al., 2009). In both series the age groups are 
similar (40-50 years), showing, respect to seniors, a peak in early childhood and a significant 
variation in mortality for hospitalized patients (48 and 14% respectively ) and oxygenation 
index [ratio of arterial oxygen pressure to fraction of inspired oxygen (PaO 2 / FoO2)], 
founding significant differences in the need for early mechanical ventilation (less than 10 
hours), renal failure, hypotension at admission or shock refractory to intravenous fluids or 
need for vasoactive drugs and elevated values of lactic dehydrogenase, although the latter 
difference was not significant. Other interesting facts included decreased arterial oxygen 
saturation in patients who required mechanical ventilation (average 71%) and severe degree 
of hypoxemia in the group of nonsurvivors (41.5 mmHg) (Bautista et al., 2010; Dominguez-
Cherit et al., 2009; Chavarría et al., 2010). For the proper management of patients with any 
acute or chronic lung disease exacerbated is important to integrate all data and knowledge. 
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13. Diagnosis 
The speed with which the diagnosis is made is directly related to virological techniques 
employed. Techniques can be used to detect viral antigens using immunofluorescence or 
ELISA (Enzyme-linked immunosorbent assay) assays, which allows having a fast and 
reliable diagnosis. Novel detection technique such as Influenza A (H1N1)-real-time PCR 
(AH1N1-RTqPCR) was recommended recently by the WHO (CDC, 2009a, 2009b; Poon et al, 
2009; Public Health 2009). This assay allows discriminating between different strains of 
seasonal and pandemic influenza. This technique uses specific primers to amplify 
specifically fragments of genes that codify the influenza virus Hemagglutinin or M2 
proteins. The RTqPCR can detect up to 5,000 copies of a gene in each sample, and it can be 
used combined set of primers for determining different viral strains in a single biological 
sample. During the A (H1N1) pandemic, this technique was implemented as a main part of 
a diagnostic platform allowing the detection of new viral mutations of the recent A (H1N1) 
pandemic strain (Public Health, 2009; Pabbaraju et al., 2009; Balish et al., 2009). For the 
determination of neutralizing antibodies, the WHO suggested hemagglutination inhibition 
test (CDC, 2009). 
The techniques used for early diagnosis of influenza directly dependent on the type, quality 
and quantity of biological sample and for the detection of viruses. On the recommendation 
of the WHO, we used different types of samples such as bronchoalveolar lavage samples, 
aspirates, nasal and nasopharyngeal swabs or aspirates (Balish et al., 2009; Ison, 2009; 
Thorpe & Darcy 2009). For patients who are intubated, it was considered the recollection of 
endotracheal aspirates (Balish et al., 2009; Thorpe & Darcy 2009).  
In order to minimize the possible spread of disease, during the sampling was used 
appropriate work equipment. For the transport of biological samples was important to 
consider the use of specific culture media for viruses as well as the use of equipment or 
refrigerants to maintain a temperature of 4°C, which help to reduce the loss of virus 
collected.  
14. Therapeutic management 
Usually, the majority of flu cases showed mild and minor symptoms or manifestations, are 
self-limited not requiring antiviral treatment instead only symptomatic measures such as 
analgesics, antipyretics like acetaminophen or ibuprofen. During the influenza pandemic 
were considered for treatment the following clinical features: persistent fever, progressive 
symptoms, risk factors such as pregnancy, obesity, infants with alarm data. When not 
requiring antiviral therapy were given directions to go back to see if they have alarm data 
such as dyspnea, fever difficult to control, bloody sputum or changes in consciousness. In 
case of children, they were monitored to the presence of changes such as cyanosis, 
tachypnea and apnea. Before treatment and for the proper management of patients were 
considered some aspects: Treatment should be initiated as soon as influenza is suspected 
since when management delayed for more than 48 hours is not very effective, in severe 
cases should be initiated as soon as possible, even if have been more than 48 hours. In cases 
of pneumonia, it has been described that treatment was effective in patients who have 
symptoms for more than 6 days, helping to decrease mortality. Treatment will probably not 
prevent the development of ARDS, or cytokine storm, but prevents serious illness and 
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death. Another important aspect is that treatment can reduce the need for hospitalization 
and length of hospital stay; in addition, there exists the need to know if comorbidity or data 
that might indicate a progressive evolution (Cabello et al, 2012 in press; CDC, 2009; Higuera 
et al., 2011; Sada, 2010; WHO, 2009b). 
14.1 Antiviral drugs 
The dose of oseltamivir administered to adult patients was 75 mg, every 12 hours for 5 days. 
In cases of pneumonia, it should use double dose, i.e. 150 mg every twelve hours, being able 
to prolong treatment for ten days. The adult dose of zanamivir was two doses of 10 mg by 
inhalation every twelve hours for 5 days having the disadvantage of producing irritation of 
the airway that could lead to bronchospasm, so caution should be exercised with patients 
with prior respiratory problems, such as asthma and chronic obstructive pulmonary disease. 
In some cases is recommended the prophylactic administration of bronchodilators prior to 
the application of zanamivir. In the case of intravenous neuraminidase inhibitor, peramivir, 
the recommended dose is 600 mg every 24 hours. Pediatric doses of oseltamivir should be 
calculated by age and weight, according to the following recommendations: 30 mg twice 
daily if ≤15 kg; 45 mg twice daily if weight is 15 to 23 kg; 60 mg twice a day for weight from 
23 to 40 kg; 75 mg twice daily if weight > 40 kg. In children under 5 years is not 
recommended the use of zanamivir while in children over 5 years old, doses are similar to 
those of adults: two inhalations of 10 mg every twelve hours (CDC, 2010; Hanshaoworakui 
et al., 2009;Kidd et al., 2009; Sada, 2010; Updated, 2009; WHO 2009b).  
During pregnancy, it has been shown that antiviral drugs are effective; however, it should 
be administered early to prevent the development of pneumonia; fortunately these drugs 
have not been associated with congenital malformations. 
14.2 Antimicrobial treatment 
In severe disease there may be some bacterial respiratory complications in these cases it can 
use the treatment guidelines for community-acquired pneumonia. In the schemes 
recommended by Mexican experts, it has decided that all patients with pneumonia should 
also receive antiviral drugs such as ceftriaxone at a dose of 2 g intravenous or intramuscular 
every 24 hours for 7 to 10 days. Patients who require mechanical ventilation are not exempt 
from acquiring a nosocomial infection, so antibiotics were used according results of 
bacteriological analyses (Sada, 2010; Updated, 2009a, 2009b). In specific cases of patients 
with influenza, in addition to specific antiviral treatment is recommended other 
symptomatic treatments such as antipyretics and anti-inflammatory drugs (paracetamol or 
ibuprofen) at useful doses. It was considered contraindicated the use of aspirin, especially in 
children and young people and their use in influenza is associated with development of 
Reye's syndrome. 
15. Pre-pandemic phase 
In Mexico, in 2003 it was created a multidisciplinary group to develop a National Plan for 
preparedness and response to pandemic avian influenza, which was completed in 2006 
(Manjarrez, 2007; Secretaría de Salud de Mexico, 2010 a). For the situation that arose in 2009, 
this Plan was resumed (Figure 5) in accordance with the recommendations of the WHO, the 
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Ministry of Health participated through the National Epidemiological Surveillance and 
Disease Control (CENAVECE), the Department of Epidemiology (DGEPI), the Coordinating 
Committee of the National Institutes of Health and High Specialty Hospitals (CCIN Salud 
HAE) in collaboration with entities of the health sector and government sector. In this 
document is showed local actions for a possible pandemic of avian influenza, in order to 
reduce cases of human infection and mortality. Main action lines of action for strategic 
activities were: 1) Dissemination and information, 2) Epidemiological surveillance, 3) 
Confirmation of the diagnosis, 4) Care for the population, 5) Strategic reserve and 6) 
Research and development. 
 
Fig. 5. National Plan for preparedness and response to pandemic influenza in Mexico. 
15.1 Pandemic phase 
The National Plan for preparedness and response to pandemic influenza in Mexico was not 
fully consolidated, requiring dissemination of guidelines and operational training as well as 
antiviral supplies in all health institutions in the country, including non-governmental 
health institutions. When detonated the alert in Mexico, it began negotiations for the 
preparation, packaging and distribution of oseltamivir to all healthcare facilities across the 
country, which reported suspected or confirmed cases of A (H1N1), which caused a delay in 
the timely administration of the first patients affected by the pandemic (Manjarrez, 2010; 
Secretaría de Salud de Mexico, 2010).  
Among the most outstanding activities was the diagnosis as a crucial part of 
epidemiological surveillance to monitor the A (H1N1) virus circulation correlating with the 
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occurrence of severe pneumonia cases. It could be proposed that this action was 
transformed to a vulnerable point of the health system and a point of discussion in the 
committees, because main resources and efforts were limited only to patients with 
pneumonia.  
Hospital authorities adopted, as strategy, reference mechanisms since the facilities were 
inadequate, especially intermediate and intensive care units where many cases required 
mechanical ventilation; in addition, care activities from specialist staff was insufficient for local 
needs. Influenza committee sessions were performed daily in order to solve the main 
problems: the shortage of human and material resources. Other problems were: limited 
coverage of seasonal influenza vaccination, access to health services, availability of information 
on health, socioeconomic level, demographic characteristics, cultural background, educational 
level, government policies on health, etc. (Secretaría de Salud de Mexico, 2010). Mexico was 
the first country that gave international epidemiological alert in March and April 2009. 
According to official reports of surveillance were involved several states including San Luis 
Potosi, Hidalgo, Queretaro and Mexico City (Central Mexico). The Secretary of Health of 
Mexico reported the viral infection on April 24th (Secretaría de Salud de Mexico, 2010), 
therefore, social distancing measures were intensified to contain the pandemic, which included 
the closure of certain public places like restaurants, schools, kindergartens, cinemas, theaters, 
foot-ball stadiums, among others, these actions were extended until May 11th to Mexico City 
and May 18th for the rest of the states. In contrast to the global alert issued by WHO, Mexican 
pandemic rose to five on a scale of 6 on April 29th (fig.6). 
15.2 Post pandemic phase 
After the pandemic, there were disseminated, through various information media, criticism 
of the decisions taken by the authorities of the Ministry of Health in Mexico, because these 
radical actions to contain the dissemination of viral infection, National economy were 
crashed. However, this strategy played an important role in advancing on the field of 
epidemiology and public health that included:  
- Improved hand hygiene in the population. 
- Control of antimicrobials through medical prescription.  
- Activation of epidemiological surveillance systems. 
- Research resources.  
- Investment in health infrastructure, including medical equipment such as mechanical 
ventilators.  
It was developed several guidelines and rules to follow, including: 
15.3 Precautions to prevent transmission in hospitals and health care 
 Preventive isolation of patients, including a combination of standard and transmission 
precautions 
 Direct contact 
 Drop spread 
 Air spread 
 According to the demands, ideally patients should stay in a room with negative 
pressure, or to use a single room whose door will remain closed most the time. When 
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institutions do not have these resources by the magnitude of the pandemic, patients 
should stay in multiple rooms or rooms specially designated for patients infected with 
influenza. The litters must be a minimum distance of 1 m.  
 Health professionals, directly involved in patient care must use high efficiency masks as 
N-95 or its equivalent, long sleeved gowns with adjustable cuffs, face shield or goggles 
and gloves. This equipment is not recommended for administrative professionals that 
do not require direct contact with these patients as is recommended face masks only.  
 It is necessary to limit the number of health professionals in direct contact with the 
patients and to limit the access to the patient environment. 
 Health professionals who attend patients with pandemic influenza should not take care 
of patients diagnosed with other disease or young children.  
 Restrict visits to a minimum.  
 Give visitors the regulation of hospital safety and personal protective equipment with 
instructions for use.  
 Encourage frequent hand washing, particularly in areas of risk by the presence of 
influenza patients. 
15.4 Security measures at an unprotected exposure of health professionals or family 
members 
1. Professionals who care for infected patients should monitor their temperature twice 
daily and report any febrile episode. If exist any sign or symptoms, the professional 
should not to participate in non-specific or direct care of patients. 
2. Health professionals who have a fever (temperature > 38°C) and have been in contact 
with patients should undergo appropriate diagnostic tests. If no other cause is 
identified, it should be assumed an influenza infection and immediately start treatment 
with oseltamivir. 
3. Healthcare professionals involved in high-risk procedures (e.g. procedures which 
generate aerosols) that begin with any signs or symptoms should consider the need for 
prophylaxis. 
15.5 Precautions for the general population during an influenza contingency 
1. Household contacts should take appropriate steps in terms of hygiene; not sharing 
utensils, avoid face to face contact with patients with confirmed or presumptive 
diagnosis and the use of high-efficiency masks and googles (e.g. N-95 type). 
2. Contacts who have shared a particular environment: home, homes of other family 
members, hospitals, schools, workplace, recreation centers, mass transport, etc., with a 
patient with confirmed or suspected influenza A (H1N1) should monitor their 
temperature twice daily as well as the appearance of symptoms within 7 days after the 
last exposure. 
3. Confirmed asymptomatic contacts should not receive oseltamivir. 
4. Symptomatic household contacts with temperature > 38°C, cough, dyspnea, diarrhea or 
other systemic symptoms, should receive empirical antiviral therapy (e.g. a dose of 75 
mg once daily for 5 days in adults and children) and undergo to diagnostic testing as 
soon as possible. 
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15.6 Preventive measures for travelers going to areas with Influenza alert 
1. People who are traveling to areas with avian influenza activity should be immunized 
with trivalent human vaccine available (seasonal), two weeks before the trip. 
2. Travelers should avoid direct contact with poultry, including chickens, ducks, or geese 
that appear healthy, in addition, these people should avoid farms or live animal 
markets, poultry, or touching surfaces contaminated with feces of poultry secretions. 
3. Travelers should take preventive measures to reduce risks of exposure through proper 
hygiene and frequent hand washing with alcohol-gel. Also, avoid eating eggs or foods 
derived from poultry that haven poorly cooked or raw. 
4. Hand washing is important when handling raw poultry for cooking, either at home or 
in business. 
5. It is necessary to recommend to travelers to consult a physician if the traveler has fever 
and respiratory symptoms during the 10 days after of returning from an affected area. 
15.7 End of the pandemic 
Health Secretary lifts the state of epidemic alert on June 30th, 2010. The latest official data, 
published by the Ministry of Health on June 19th, 2010, indicated that Mexico recorded 
72,548 confirmed cases and 1,316 confirmed deaths, representing a mortality of 1.8%. 
Seventy percent of deaths corresponded to the age group between 20 and 54 years old, and 
39.8% of them did not find any pathological history relevant to death (Secretaría de Salud de 
México, 2010a, 2010b). 
 
Fig. 6. Confirmed cases according to the date of symptoms on the population 
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16. Social response to the epidemic 
The first manifestations of the epidemic in Mexico caused significant morbidity and 
mortality in the population, with implications for high psychological, social and economic 
impact (Cruz & Corrales 2010). With the emergence of a new influenza virus, the growth of 
reports of confirmed cases of illness and deaths caused the mass media fix their attention on 
it, the news spread very fast because it had little knowledge of the virus, generated a great 
concern throughout the population, disrupting social stability that had already been altered 
for several reasons.  
The social response to an epidemic is given in circumstances that occur in time, space, era 
and culture, and serve to properly interpret phenomena according to social reality. An 
important aspect to understand this response is the psychosocial vulnerability, an internal 
condition of a subject or a group of subjects exposed to threatening or traumatic event, 
which corresponds to the perception of risk in which the person has to be damaged. 
Perception can be objective (real threat) or subjective (built by the subject, it may be 
consistent with reality or the risk can be distorted and exaggerated or minimized). Since the 
many kinds of risk perception, the situation led to a series of emotions and behaviors 
appropriate or inappropriate to the society. Adequate collective behaviors refer to protection 
measures that will allow reducing the spread of the virus and thereby reduce the number of 
cases, eliminating to fall into chaos. Inappropriate behaviors such as spreading rumors that 
encourage mass hysteria or that the situation is unreal will generate maladaptive behaviors 
that gradually lead to social disorganization (Cruz & Corrales 2010). 
One of the feelings experienced by people was the collective fear, which is characterized by 
sharing an intense fear in a social group. This fear can be adaptive, allowing people to grade 
their level of risk and therefore take steps to protect themselves. As example, masks, 
antibacterial, vitamin supplements such as vitamin C and subsequently antiviral drugs were 
sold out. The collective fear can lead to exaggerated and disproportionate behavior of 
reality; one example: the population stopped eating pork since fear of contagion, as the 
initiation of pandemic was related to the swine flu.  
Fear can turn into panic, manifested by an intense fear that can produce primitive reactions, 
messy and can take led to violence and discrimination (Cruz & Corrales 2010). Mexicans, 
who were abroad or want to leave the country, were badly treated and their individual 
rights breached. Some countries set restrictions on commercial and business flights that 
were suspended. Discrimination against Mexico and its people was very severe.  
The coordinated effort of health workers, authorities, officials and civilians were able to 
maintain adequate adjustment mechanisms, promoting the restructuring of social welfare 
and allowing the development of active strategies for protecting the population and reduce 
the spread of the virus and ultimately, drive the epidemic successfully. 
17. Detection of humoral immune response in different  populations 
The new influenza virus circulated and remained stable in the environment, easily entering 
the body. The immune system is activated to produce antibodies, which in any way prevent 
or reduce the development of   the disease. For information from the presence of specific 
antibodies against the new influenza virus, we performed a multicenter study, which were 
obtained several results mentioned here only a brief summary of some of them. 
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1. Anti-virus influenza A (H1N1) pandemic in people at different levels of exposure to the 
virus, whose aim was to: Identify and compare the presence of specific serum Ab 
against the new virus influenza A (H1N1) and GEA INER staff at different levels of 
exposure. This study concluded that greater exposure, higher titers of antibodies and 
the application of the specific vaccine enhanced the response. 
2. Prevalence of influenza virus A (H1N1) in blood donors. In this study analyzed 241 
samples of sera from donors, by the method of hemagglutination inhibition (HI) for 
antibodies against influenza virus seasonal and pandemic virus. Samples were taken 
from November 2008 to May 2009. We found that in 65 (27%) were detected antibodies 
to the novel influenza virus and seasonal influenza virus 87 (36%). Found that only 26 
(10%) samples were positive for both viruses. The titles ranged from 1:10 to 1:80. By 
comparing the results of the pre-pandemic period the epidemic found a statistically 
significant difference [ OR 6.1,95% (2.34-14.1) p <0.0001]. Concluded that there are few 
studies showing the prevalence of the pandemic virus in a healthy population without 
recent illness. Although the results are few, indicate that the population was in contact 
with the new virus probably since 2008 the end of 2008 antibodies were detected and 
the prevalence in this population ranged from 9% pre-epidemic period and 36% 
epidemic period. 
3. Another objective was to compare the presence of antibodies against the new influenza 
virus and seasonal influenza viruses INER staff and a Technology University of 
Tecamac (UT).  This study concluded that the greatest number of people with 
antibodies to both viruses was INER, being significant in the case of the new virus, 
indicating that their exposure was greater when dealing with infected patients. It is 
interesting to note that INER staff is annually vaccinated against the virus, but number 
of people with seasonal virus antibodies was low. 
The presence of antibodies may provide guidance on some aspects such as proximity or 
degree of exposure to the virus the ability to respond immunologically to viral stimulation, 
virus circulation:the possibility of partial or weak protection of a vaccine. 
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